Hindustan Bio Sciences Ltd

Results & AGM

• Board approves unaudited standalone results for quarter ended 30 June 2026.
• Limited Review Report issued by statutory auditors.
• 34th AGM fixed for 30 September 2026 at 10:00 AM.
• Notice, Directors' Report and Corporate Governance Report approved.
• Mr. VBSS Prasad appointed Scrutinizer for remote e-voting.
• Single segment: Trading of Pharmaceuticals.
• Earnings per equity share for continuing operations negative.
• Auditor's review: no material misstatement identified.

Dematerialisation activity

• RTA reports no dematerialisation certificates received for Hindustan Bio Sciences Ltd from April 2026 to June 2026.
• No dematerialisation/rematerialisation activities occurred in the quarter ended 30 June 2026.

Financial Performance 📊

• Revenue from operations rose to Rs 38.25 crore in Q3 FY26 from Rs 30.00 crore YoY.
• Total revenue increased to Rs 40.03 crore in Q3 FY26 versus Rs 30.88 crore in Q3 FY25.
• EBITDA improved to Rs 8.20 crore profit in Q3 FY26 from a Rs 5.85 crore loss in Q3 FY25.
• Profit after tax was Rs 8.20 crore in Q3 FY26 versus a loss of Rs 5.85 crore in Q3 FY25.
• EPS was Rs 0.08 basic and diluted in Q3 FY26, compared to negative Rs 0.08 basic and Rs 0.06 diluted in Q3 FY25.
• No exceptional or extraordinary items reported in Q3 FY26.

Expenses & Costs

• Employee benefit expenses increased to Rs 4.97 crore in Q3 FY26 from Rs 3.26 crore in Q3 FY25.
• Depreciation and amortization expenses rose to Rs 1.19 crore in Q3 FY26 from Rs 0.09 crore in Q3 FY25.
• Other expenses increased to Rs 1.92 crore in Q3 FY26 from Rs 0.84 crore in Q3 FY25.
• Finance costs remained stable at Rs 0.05 crore in Q3 FY26.

Corporate & Governance

• Board approved Q3 FY26 unaudited financial results and limited review report on 31-Jan-2026.
• Auditor's review report expressed no material misstatement or qualification for Q3 FY26 results.

Balance Sheet & Capital

• Paid-up equity capital stable at Rs 20.502 crore with Rs 2 face value per share.
• Reserves excluding revaluation reserves stood at negative Rs 114.52 crore as per previous year balance sheet.

Business Model

• Hindustan Bio Sciences operates in pharmaceuticals manufacturing, reporting standalone quarterly financials.

Financial Performance 📊

• Board approved unaudited standalone financial results for quarter ended 31 December 2025.
• Total revenue for the quarter was Rs. 40.03 crore; profit before tax was Rs. 8.20 crore.
• Profit after tax for the quarter was Rs. 8.20 crore; basic earnings per share was Rs. 0.08.
• Paid-up equity capital stood at Rs. 20.502 crore with a face value of Rs. 2 per share.
• Auditor’s review report expressed no material misstatements or qualifications on the unaudited results.
• Financial results prepared as per Indian Accounting Standard 34 and approved by the Board.

Target Entity and Acquisition Details

• Target: Hindustan Bio Sciences Limited, pharmaceutical sector, India-based.
• Acquisition date: 22 January 2026 via open market purchase.
• Shares acquired: 15,000 shares, representing 0.14% of total share capital.
• Post-acquisition shareholding: Bosco Armando Menezes 2.63%, Emily Bosco Menezes 2.49%.
• Total equity share capital: Rs. 2,05,01,600 comprising 1,02,50,800 shares of Rs. 2 each.
• Acquisition is not a related party transaction.

Regulatory and Consideration

• No regulatory or governmental approvals mentioned.
• Consideration details and acquisition cost not disclosed.